Teleflex Incorporated (NYSE:TFX)‘s stock had its “buy” rating reissued by equities researchers at Stephens in a research report issued on Monday. They currently have a $270.00 price target on the medical technology company’s stock, up from their prior price target of $230.00. Stephens’ price objective points to a potential upside of 11.68% from the company’s previous close.

Other research analysts have also recently issued reports about the stock. Needham & Company LLC boosted their target price on shares of Teleflex from $228.00 to $237.00 and gave the stock a “buy” rating in a research report on Tuesday, September 5th. Leerink Swann boosted their target price on shares of Teleflex from $215.00 to $220.00 and gave the stock a “market perform” rating in a research report on Friday, June 9th. KeyCorp reissued a “hold” rating on shares of Teleflex in a research report on Wednesday, September 6th. Morgan Stanley raised shares of Teleflex from an “equal weight” rating to an “overweight” rating and boosted their target price for the stock from $220.00 to $274.00 in a research report on Wednesday, September 6th. Finally, Zacks Investment Research raised shares of Teleflex from a “hold” rating to a “buy” rating and set a $265.00 target price on the stock in a research report on Friday. One analyst has rated the stock with a sell rating, one has issued a hold rating and eight have given a buy rating to the stock. Teleflex has a consensus rating of “Buy” and an average target price of $260.75.

Shares of Teleflex (TFX) traded up 0.38% during midday trading on Monday, hitting $242.68. 301,975 shares of the stock were exchanged. The firm has a market cap of $10.93 billion, a P/E ratio of 46.41 and a beta of 1.05. The firm has a 50 day moving average of $216.57 and a 200 day moving average of $205.08. Teleflex has a 12-month low of $136.53 and a 12-month high of $243.54.

Teleflex (NYSE:TFX) last posted its earnings results on Thursday, August 3rd. The medical technology company reported $2.04 EPS for the quarter, topping analysts’ consensus estimates of $1.91 by $0.13. Teleflex had a net margin of 12.36% and a return on equity of 16.12%. The business had revenue of $528.60 million for the quarter, compared to analysts’ expectations of $518.98 million. During the same period in the previous year, the company posted $1.89 earnings per share. The business’s revenue for the quarter was up 11.6% compared to the same quarter last year. Equities analysts forecast that Teleflex will post $8.28 EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “Teleflex’s (TFX) “Buy” Rating Reiterated at Stephens” was first published by American Banking News and is the property of of American Banking News. If you are accessing this story on another site, it was stolen and reposted in violation of US & international trademark and copyright law. The original version of this story can be read at https://www.americanbankingnews.com/2017/09/25/teleflexs-tfx-buy-rating-reiterated-at-stephens.html.

In related news, Director Stephen K. M.D. Klasko sold 200 shares of the company’s stock in a transaction on Tuesday, August 1st. The shares were sold at an average price of $208.41, for a total value of $41,682.00. Following the sale, the director now directly owns 8,080 shares of the company’s stock, valued at $1,683,952.80. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders sold 600 shares of company stock worth $125,652 over the last ninety days. 2.39% of the stock is currently owned by corporate insiders.

A number of institutional investors and hedge funds have recently bought and sold shares of TFX. Janus Henderson Group PLC raised its holdings in Teleflex by 50,429.2% in the second quarter. Janus Henderson Group PLC now owns 1,816,020 shares of the medical technology company’s stock valued at $377,296,000 after acquiring an additional 1,812,426 shares in the last quarter. Koch Industries Inc. raised its holdings in Teleflex by 47,174.3% in the second quarter. Koch Industries Inc. now owns 959,669 shares of the medical technology company’s stock valued at $955,000 after acquiring an additional 957,639 shares in the last quarter. Marshall Wace North America L.P. raised its holdings in Teleflex by 137.4% in the second quarter. Marshall Wace North America L.P. now owns 518,462 shares of the medical technology company’s stock valued at $107,840,000 after acquiring an additional 300,069 shares in the last quarter. Principal Financial Group Inc. raised its holdings in Teleflex by 93.5% in the second quarter. Principal Financial Group Inc. now owns 610,398 shares of the medical technology company’s stock valued at $126,816,000 after acquiring an additional 294,935 shares in the last quarter. Finally, FMR LLC raised its holdings in Teleflex by 46.5% in the first quarter. FMR LLC now owns 811,764 shares of the medical technology company’s stock valued at $157,263,000 after acquiring an additional 257,649 shares in the last quarter. 89.75% of the stock is currently owned by hedge funds and other institutional investors.

About Teleflex

Teleflex Incorporated is a provider of medical technology products. The Company designs, develops, manufactures and supplies single-use medical devices used by hospitals and healthcare providers for diagnostic and therapeutic procedures in critical care and surgical applications. The Company operates through six segments: Vascular North America; Anesthesia North America; Surgical North America; Europe, the Middle East and Africa (EMEA); Asia, and Original Equipment Manufacturer (OEM).

Analyst Recommendations for Teleflex (NYSE:TFX)

Receive News & Ratings for Teleflex Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teleflex Incorporated and related companies with MarketBeat.com's FREE daily email newsletter.